{{ __('Your cart') }}0
0,00 £
0
items
0,00 £
Cancer is a complex disease characterised by the uncontrolled growth of abnormal cells in the body. Modern medical science has developed numerous treatment approaches to combat this condition, with pharmaceutical interventions playing a crucial role alongside surgery and radiotherapy. Understanding the available treatment options empowers patients and their families to make informed decisions about their care.
Several key treatment modalities form the foundation of contemporary cancer management. Chemotherapy remains one of the most established cancer treatments, working by targeting rapidly dividing cells. Targeted therapies represent a more recent advancement, designed to attack specific cancer cell characteristics. Immunotherapy harnesses the body's own immune system to recognise and destroy cancer cells. Hormone therapies are particularly effective for certain cancer types that depend on hormonal signals to grow.
Each treatment approach has different mechanisms and applications, depending on the cancer type, stage, and individual patient factors. Your oncology team will recommend the most suitable treatment based on comprehensive diagnostic testing and your overall health status.
Chemotherapy uses powerful medications to destroy cancer cells throughout the body. These cytotoxic drugs work by interfering with cell division and DNA replication, preventing cancer cells from multiplying. Common chemotherapy medications available in the United Kingdom include:
These medications are typically administered intravenously, though some formulations exist as oral tablets. Chemotherapy often follows specific cycles, allowing the body recovery time between treatments. Side effects vary depending on the drug and individual tolerance but may include nausea, hair loss, fatigue, and increased infection risk. Your medical team carefully balances the therapeutic benefits against potential adverse effects when selecting appropriate regimens.
Targeted therapies represent a significant advancement in cancer treatment, attacking specific molecular characteristics of cancer cells. These medications work by blocking particular proteins or genetic mutations that drive cancer growth. Genetic testing before treatment ensures patients receive medications matched to their tumour characteristics, representing true personalised medicine.
Several innovative targeted therapies have transformed cancer outcomes. Herceptin (trastuzumab) targets HER2-positive breast cancers, significantly improving outcomes for patients with this genetic marker. Tyrosine kinase inhibitors like Imatinib revolutionised chronic myeloid leukaemia treatment by targeting the BCR-ABL fusion protein. Erlotinib and Gefitinib target epidermal growth factor receptors in lung cancer patients with specific mutations. Bevacizumab inhibits angiogenesis, preventing tumour blood vessel formation, and is used in colorectal, lung, and breast cancers.
BRAF inhibitors such as Vemurafenib and Dabrafenib are effective for melanomas with BRAF mutations, whilst MEK inhibitors like Trametinib often work synergistically with BRAF inhibitors. PD-L1 inhibitors including Nivolumab and Pembrolizumab activate immune responses against cancer cells. These therapies generally produce fewer side effects than traditional chemotherapy because they specifically target cancer cells rather than all rapidly dividing cells.
Hormonal therapies treat cancers that depend on hormonal signals for growth, particularly breast and prostate cancers. Tamoxifen remains a cornerstone breast cancer medication, blocking oestrogen receptors on cancer cells and preventing growth stimulation. Aromatase inhibitors including Letrozole, Anastrozole, and Exemestane reduce oestrogen production in post-menopausal women, effectively treating hormone-receptor-positive breast cancers. Fulvestrant acts as a selective oestrogen receptor degrader, destroying oestrogen receptors on cancer cells.
For prostate cancer, androgen deprivation therapies block testosterone production or action. Goserelin, a GnRH agonist, reduces testosterone levels and is administered as monthly or quarterly injections. Bicalutamide and Enzalutamide are androgen receptor antagonists used in prostate cancer treatment. CDK4/6 inhibitors like Palbociclib, Ribociclib, and Abemaciclib enhance hormonal therapy effectiveness in advanced breast cancer.
These medications often become maintenance therapies, continuing for extended periods to prevent recurrence. Hormonal therapies typically cause different side effects compared to chemotherapy, including hot flushes, joint pain, and mood changes. Treatment duration depends on cancer stage and individual factors, with some patients receiving therapy for several years. Combining hormonal agents with other treatment modalities often produces superior outcomes compared to monotherapy approaches.
Beyond primary cancer treatments, supportive medications manage symptoms and treatment side effects, significantly improving quality of life. Anti-emetic medications prevent chemotherapy-induced nausea and vomiting; Ondansetron and Granisetron are commonly prescribed, with Metoclopramide providing additional anti-nausea benefits through different mechanisms.
Pain management utilises opioid medications including Morphine and Oxycodone for severe cancer pain, alongside non-opioid options like Paracetamol and NSAIDs. Bisphosphonates such as Zoledronic acid prevent bone complications in cancers affecting skeletal systems. Colony-stimulating factors like Filgrastim prevent infection by boosting white blood cell production during chemotherapy. Corticosteroids reduce inflammation and manage various symptoms.
Psychological support remains essential throughout cancer treatment. Antidepressants address psychological effects of cancer diagnosis and treatment, whilst sleep aids help manage insomnia common during cancer care. Antibiotic and antifungal medications prevent infections when immune systems are compromised. Nutritional support through specialised supplements addresses weight loss and nutritional deficiencies. Anxiety management with anxiolytic medications supports psychological well-being. Complementary approaches including acupuncture for nausea and counselling services provide holistic support. Your healthcare team will tailor supportive care to your specific needs, reviewing medications regularly as treatment progresses.
Clinical trials provide access to cutting-edge cancer treatments not yet widely available, offering hope for patients with limited standard options. The United Kingdom hosts numerous active cancer trials through NHS Trusts and independent research centres. Participation in clinical trials requires careful consideration, including discussing potential benefits and risks with your oncology team. Trial protocols ensure rigorous safety monitoring and ethical oversight.
Emerging therapeutic approaches offer exciting possibilities for cancer patients. CAR-T cell therapies represent revolutionary immunotherapy approaches, genetically modifying a patient's own immune cells to attack cancer. Tisagenlecleucel, an approved CAR-T therapy, demonstrates remarkable results in certain leukaemias and lymphomas. Checkpoint inhibitors continue evolving, with new combinations showing improved efficacy. Antibody-drug conjugates combine targeted antibodies with cytotoxic payloads for enhanced precision, whilst bispecific antibodies simultaneously engage cancer cells and immune cells, amplifying therapeutic responses.
Additional innovative approaches include gene therapy addressing underlying genetic causes of certain cancers and oncolytic virus therapies using modified viruses to destroy cancer cells selectively. Precision medicine trials match treatments to individual tumour genetics and immunological profiles, representing the future of personalised cancer care. Many patients derive both personal benefit and contribute to advancing cancer knowledge through trial participation. NHS clinical trial infrastructure connects eligible patients with appropriate studies. Speaking with your consultant about trial opportunities may provide access to innovative treatments whilst supporting cancer research advancement.
